ArticleEuropean urology open science2025
Impact of Surgical Margin Status and Tumor Volume on Mortality After Robotic Radical Prostatectomy.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Positive surgical margins after robot-assisted radical prostatectomy Long-term oncologic consequences.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Article
- Comment on "Oncologic and perioperative outcomes following robot-assisted radical prostatectomy in morbidly obese patients: a systematic review and meta-analysis".Journal of robotic surgery · 2025Article
- Commentary on "Twenty-Seven Years After Sex Reassignment Surgery in Female Transgender Patients: Is Prolapse of the Neovagina an Issue?"International urogynecology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Positive surgical margins (PSMs) following radical prostatectomy (RP) have been seen as inherently unfavorable. However, a large international multi-institutional study recently revealed that unifocal PSMs (UPSMs) had no impact on prostate cancer-specific mortality (PCSM), whereas multifocal PSMs (MPSMs) did. Our aim was to assess the relative impact of PSMs versus percentage tumor volume (PTV) on PCSM. Methods: We analyzed data for 1552 patients who underwent robot-assisted RP performed by a single surgeon between 2002 and 2018 at a tertiary referral center with up to 15-yr follow-up. Patients were divided into negative surgical margin (NSM), UPSM, and MPSM groups, with PTV stratification using a cutoff of 40%. The primary outcome was stepwise multivariate regression analysis of predictors of PCSM (pT stage, pathological Gleason grade group, PTV, UPSM, and MPSM). The secondary outcome was the risk of 15-yr PCSM via Kaplan-Meier analysis. Key findings and limitations: The group with 40-100% PTV was older and presented with more advanced grade and stage. High PTV was significantly associated with greater risk of PSM, biochemical recurrence, PCSM, and overall mortality at 15 yr ( Conclusions and clinical implications: Our study further challenges the belief that MPSMs inherently have an adverse impact on PCSM. Instead, MPSMs appear to signify more aggressive underlying disease that predominantly drives oncological outcomes. We recommend considering PTV as a more reliable predictor of PCSM. While avoidance of PSMs remains a critical surgical principle, this goal in prostate cancer needs to be weighed against urinary and sexual function outcomes. Patient summary: After surgery to remove the prostate in men with prostate cancer, samples from the edge of the prostate that are positive for tumor cells are called positive surgical margins (PSMs). Results from our study show that a PSM on its own is not necessarily an adverse factor. However, PSMs may be a sign of higher severity of prostate cancer. We found that men with a high tumor volume have a higher risk of dying from their prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.